17.20
0.34 (2.05%)
Penutupan Terdahulu | 16.86 |
Buka | 16.83 |
Jumlah Dagangan | 232,877 |
Purata Dagangan (3B) | 319,082 |
Modal Pasaran | 553,152,000 |
Harga / Jualan (P/S) | 92.66 |
Harga / Buku (P/B) | 1.65 |
Julat 52 Minggu | |
Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
Margin Operasi (TTM) | -2,852.71% |
EPS Cair (TTM) | -2.83 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 33.10% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 0.43% |
Nisbah Semasa (MRQ) | 15.98 |
Aliran Tunai Operasi (OCF TTM) | -90.87 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -52.44 M |
Pulangan Atas Aset (ROA TTM) | -20.04% |
Pulangan Atas Ekuiti (ROE TTM) | -28.73% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Dianthus Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
Konsensus Penganalisis | 5.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 4.5 |
Purata Bergerak Teknikal | -2.5 |
Osilator Teknikal | -2.5 |
Purata | 1.13 |
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody. |
|
Sektor | Healthcare |
Industri | Biotechnology |
% Dimiliki oleh Orang Dalam | 7.87% |
% Dimiliki oleh Institusi | 119.90% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 50.00 (Baird, 190.70%) | Beli |
Median | 45.00 (161.63%) | |
Rendah | 40.00 (HC Wainwright & Co., 132.56%) | Beli |
Purata | 45.00 (161.63%) | |
Jumlah | 2 Beli | |
Harga Purata @ Panggilan | 18.84 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Baird | 13 May 2025 | 50.00 (190.70%) | Beli | 18.84 |
HC Wainwright & Co. | 13 May 2025 | 40.00 (132.56%) | Beli | 18.84 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
29 May 2025 | Pengumuman | Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference |
22 May 2025 | Pengumuman | Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors |
12 May 2025 | Pengumuman | Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results |
05 May 2025 | Pengumuman | Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September |
29 Apr 2025 | Pengumuman | Dianthus Therapeutics to Participate in Two Upcoming Investor Events |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |